# Baricitinib in Hospitalized Covid-19 Patients With Diabetes Mellitus

> **NCT04970719** · PHASE3 · WITHDRAWN · sponsor: **Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders**

## Conditions studied

- COVID-19 Pneumonia

## Interventions

- **DRUG:** Baricitinib
- **DRUG:** Dexamethasone
- **DRUG:** Remdesivir

## Key facts

- **NCT ID:** NCT04970719
- **Lead sponsor:** Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-07-10
- **Primary completion:** 2021-12
- **Final completion:** 2021-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** adequate cases were not available
- **Last updated:** 2024-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04970719

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04970719, "Baricitinib in Hospitalized Covid-19 Patients With Diabetes Mellitus". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04970719. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*